Free shipping on all U.S. orders over $250 · Local pickup available in Morgan Hill, CA
PureLab Performancepurelabperformance.com
Research compoundRecovery & Tissue ResearchFS344

Follistatin-344

Follistatin-344 is the 344-amino-acid precursor form of human follistatin, a natural glycoprotein that binds myostatin and activins. Nearly all published research delivers it as a gene (AAV vector) rather than as a peptide, in mice, monkeys and one small human trial.

Evidence: limited · Gene-delivery studies in mice and monkeys; one small human trial

At a glance

Class
Myostatin / activin-binding glycoprotein
Developer
No pharmaceutical developer for the peptide; studied as an AAV gene vector by academic groups
FDA status
Not FDA-approved
Human data
One phase 1/2a open-label gene-delivery trial, 6 adults
Animal / lab data
Mouse genetic and gene-delivery studies; one primate gene-delivery study

Where it’s been studied

12
  • 1Skeletal muscleAAV1-FS344 into quadriceps, cynomolgus macaques (2009); mouse models (2010, 2018)
  • 2Reproductive hormonesSafety monitoring in macaques (2009)

Mechanism studied

Follistatin is established as a binding protein that neutralizes myostatin and activins, members of the TGF-beta family that limit muscle growth [1]. In mice, reducing the body's own follistatin produced smaller muscles, and the effect persisted partly without myostatin, supporting a role for activin A as well [1]. FS344 is processed in the body to the shorter FS315 form; gene-delivery studies inject an AAV vector so muscle cells make the protein locally [2][3].

What the research shows

StudyModelReported resultSource
Primate gene-delivery study [2]Other animal
Six cynomolgus macaques given AAV1-FS344 into the quadriceps (two promoter groups) vs untreated controls, up to 15 months
Quadriceps circumference up ~10-15%; fiber diameter 87.7 vs 65.5 µm (CMV group vs controls); no organ, immune or reproductive-hormone changes reportedPeer-reviewed
Sci Transl Med 2009
Phase 1/2a gene-delivery trial [3]Human
6 adults with a dystrophin gene variant, open-label, two ascending-level cohorts of 3, AAV1.CMV.FS344 into quadriceps
Primary endpoint: 6-minute walk distance. PublishedPeer-reviewed
Mol Ther 2015
Follistatin knockout study [1]Mouse
Mice with one copy of the follistatin gene removed, including on a myostatin-null background; cardiotoxin muscle model
Smaller muscles, shift toward oxidative fibers, lower tetanic force; effect partly retained without myostatinPeer-reviewed
Mol Endocrinol 2010
AAV1-follistatin in TIC-DUX4 mice [4]Mouse
TIC-DUX4 transgenic mouse model given AAV1-follistatin into leg muscles
Researchers reported larger muscle size and higher strength measuresPeer-reviewed
JCI Insight 2018

Human trials are listed for research context only; outcomes are reported in the linked publications. Animal and lab results do not establish effects in humans.

Not currently stocked

PureLab does not carry Follistatin-344 yet. Research demand decides what we add next; leave your email and we’ll tell you when it’s available.

More in Recovery & Tissue Research

Sources

  1. Lee SJ et al. (2010). doi:10.1210/me.2010-0127 Source
  2. Kota J et al. (2009). doi:10.1126/scitranslmed.3000112 Source
  3. Mendell JR et al. (2015) Source
  4. Giesige CR et al. (2018) Source
For research use only. Not for human or veterinary use. Not a drug, food or cosmetic, and not intended to diagnose, treat, cure or prevent any disease. This library summarizes published research for educational purposes. PureLab Performance Inc.